Observation

New study from Gain.pro - Private equity: Job killer or growth booster?

Retrieved on: 
Monday, March 18, 2024

LONDON, March 18, 2024 /PRNewswire/ -- Landmark bankruptcies and restructurings such as those involving Four Seasons Healthcare (UK), Windreich (Germany) and Alteo (France) have created a challenging narrative in Europe around PE-ownership. In response, politicians like Jeremy Corbyn in the UK have spoken out against further growth of the sector, fearing job losses and financial instability.

Key Points: 
  • A novel study debunks the myth that Private Equity (PE) ownership negatively impacts companies and their workers.
  • In response, politicians like Jeremy Corbyn in the UK have spoken out against further growth of the sector, fearing job losses and financial instability.
  • Private market intelligence provider Gain.pro, recently conducted a landmark study proving these isolated cases making headlines are far from representative.
  • The report data is derived from the largest-of-its-kind study of European private companies.

SinoCorrugated South 2024 to offer more automation solutions on site

Retrieved on: 
Friday, March 15, 2024

Whether you are looking for fully automated corrugators, printing lines, post-processing equipment or whole-plant logistics systems, the SinoCorrugated South 2024 has a complete offering.

Key Points: 
  • Whether you are looking for fully automated corrugators, printing lines, post-processing equipment or whole-plant logistics systems, the SinoCorrugated South 2024 has a complete offering.
  • As an exhibition under the WEPACK series hosted by RX(China), SinoCorrugated South 2024 will be held in conjunction with SinoFoldingCarton 2024, Dprint 2024, SinoPaper South 2024, Food Pack&Tech 2024 and PACKCON 2024 with a display area of over 120,000 square metres.
  • The exhibition will offer many brands of automated and intelligent equipment, which will demonstrate real order star-up on site.
  • If you want to see a full array of automated and intelligent equipment for paperboard and carton processing, you must attend the SinoCorrugated South 2024 from April 10 to 12 at the Shenzhen World.

From Pickleball to Archery, Cunard Reveals Queen Anne Daytime Activities

Retrieved on: 
Thursday, March 14, 2024

Pickleball is a mixture of tennis, badminton, and table tennis and can be played by singles or in pairs, either indoors or outside, and Queen Anne's top deck will boast its very own state-of-the-art Pickleball court.

Key Points: 
  • Pickleball is a mixture of tennis, badminton, and table tennis and can be played by singles or in pairs, either indoors or outside, and Queen Anne's top deck will boast its very own state-of-the-art Pickleball court.
  • Katie McAlister, President of Cunard, said: "Whether it's pickleball, archery, or world-class shows and lectures, Cunard is committed to providing guests with a wealth of activities to choose from whatever mood or interest may take them.
  • For more information about Cunard or to book a voyage, contact your Travel Advisor, call Cunard at 1-800-728-6273, or visit www.cunard.com .
  • For Travel Advisors interested in further information, please contact your Business Development Manager, visit OneSourceCruises.com , or call Cunard at 1-800-528-6273.

Focused Labs and Honeycomb.io Announce Strategic Partnership to Propel Modernization and Observability Practices

Retrieved on: 
Tuesday, March 12, 2024

DENVER, March 12, 2024 /PRNewswire/ -- In a move that underscores their commitment to driving technological advancement and operational excellence, Focused Labs and Honeycomb.io are excited to announce a strategic partnership aimed at modernizing legacy systems and enhancing observability practices.

Key Points: 
  • DENVER, March 12, 2024 /PRNewswire/ -- In a move that underscores their commitment to driving technological advancement and operational excellence, Focused Labs and Honeycomb.io are excited to announce a strategic partnership aimed at modernizing legacy systems and enhancing observability practices.
  • This collaboration brings together Focused Labs' expertise in building bespoke software solutions with Honeycomb's innovative observability platform to offer an unprecedented white-glove experience to customers.
  • The partnership between Focused Labs and Honeycomb.io represents a pivotal moment for both our companies and, more importantly, for our clients.
  • Honeycomb.io enables our customers to prioritize the modernization of their legacy using observation and data to drive value" - Austin Vance, CEO of Focused Labs.

G42 Develops BoardNavigator to Reimagine Boardroom Dynamics

Retrieved on: 
Tuesday, March 12, 2024

ABU DHABI, UAE, March 12, 2024 /PRNewswire/ -- G42, the leading UAE-based technology group announced the development of BoardNavigator, an AI board companion set to transform corporate strategy and governance. The new AI tool, planned to be available to organizations worldwide, will analyze large proprietary and public data sets to support board members in their decision-making processes.

Key Points: 
  • ABU DHABI, UAE, March 12, 2024 /PRNewswire/ -- G42, the leading UAE-based technology group announced the development of BoardNavigator, an AI board companion set to transform corporate strategy and governance.
  • BoardNavigator will enjoy the security, privacy, and compliance features of Microsoft Azure, helping customers with their regulatory obligations.
  • Kiril Evtimov, Group Chief Technology Officer, G42, said: "The use of AI in the boardroom is a gamechanger.
  • G42 intends to initially deploy BoardNavigator within sectors where it boasts significant expertise, including energy, health, finance, and technology.

G42 Develops BoardNavigator to Reimagine Boardroom Dynamics

Retrieved on: 
Tuesday, March 12, 2024

ABU DHABI, UAE, March 12, 2024 /PRNewswire/ -- G42, the leading UAE-based technology group announced the development of BoardNavigator, an AI board companion set to transform corporate strategy and governance. The new AI tool, planned to be available to organizations worldwide, will analyze large proprietary and public data sets to support board members in their decision-making processes.

Key Points: 
  • ABU DHABI, UAE, March 12, 2024 /PRNewswire/ -- G42, the leading UAE-based technology group announced the development of BoardNavigator, an AI board companion set to transform corporate strategy and governance.
  • BoardNavigator will enjoy the security, privacy, and compliance features of Microsoft Azure, helping customers with their regulatory obligations.
  • Kiril Evtimov, Group Chief Technology Officer, G42, said: "The use of AI in the boardroom is a gamechanger.
  • G42 intends to initially deploy BoardNavigator within sectors where it boasts significant expertise, including energy, health, finance, and technology.

Creating a Better Environment for Remote Drug Testing Results

Retrieved on: 
Tuesday, March 12, 2024

INDIANAPOLIS, March 12, 2024 /PRNewswire/ -- Innovations in remote drug testing technology are allowing observers to actively improve a testing environment, leading to clearer observations and higher validity in result interpretation.

Key Points: 
  • INDIANAPOLIS, March 12, 2024 /PRNewswire/ -- Innovations in remote drug testing technology are allowing observers to actively improve a testing environment, leading to clearer observations and higher validity in result interpretation.
  • Remote drug tests conducted with eRAMx Live Remote Drug Testing allow an observer to activate a donor's flashlight, front camera and rear camera on demand.
  • The feature was designed for virtual observations in remote, low-light settings such as darkened rooms or nighttime job sites.
  • "We have developed the most flexible and cost effective virtual drug testing platform in the industry today, while maintaining the integrity of each and every test performed," Milner said.

New Data to be Presented for BioMarin's VOXZOGO® (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Retrieved on: 
Tuesday, March 12, 2024

SAN RAFAEL, Calif., March 12, 2024 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate VOXZOGO's positive impact on quality of life. 

Key Points: 
  • Andrew Dauber, M.D., will present positive results from his investigator-sponsored Phase 2 study of VOXZOGO in children with hypochondroplasia.
  • The annualized growth velocity (AGV) increased from 5.12 cm/year during the observation period to 6.93 cm/year during the treatment period (mean difference: 1.81 cm/year, p
  • In late 2023, BioMarin launched the pivotal clinical trial program studying the safety and efficacy of VOXZOGO in children with hypochondroplasia.
  • "Our studies showed that increasing height with long-term administration of VOXZOGO can result in meaningful improvements in quality-of-life measures for children with achondroplasia."

ThinkAndor® AI-first Technology Poised to Reshape Care Delivery with Ambient Nursing and Staff Documentation

Retrieved on: 
Monday, March 11, 2024

Leveraging cutting-edge AI, ThinkAndor® supports an AI-first conversational documentation solution for ambient nursing and staff documentation.

Key Points: 
  • Leveraging cutting-edge AI, ThinkAndor® supports an AI-first conversational documentation solution for ambient nursing and staff documentation.
  • "Our AI technology is able to ambiently perform nursing & staff documentation, observation, and orchestrate workflows across the care continuum – for in-person care and virtual care."
  • One of the biggest gaps in healthcare, including at Orlando Health, is the absence of ambient nursing and staff documentation.
  • The ongoing innovation partnership with Andor Health is delivering on an efficient, AI-first ambient nursing and staff documentation solution that complements ambient documentation solutions generally available through other vendors for physicians.

How medieval chroniclers interpreted solar eclipses and other celestial events

Retrieved on: 
Friday, April 5, 2024

Medieval monastic thinkers often recorded celestial events such as eclipses.

Key Points: 
  • Medieval monastic thinkers often recorded celestial events such as eclipses.
  • Most medieval observation of the heavens was by eye.
  • Chroniclers, if not observing the event themselves, would rely on an eyewitness or other written records for the details.
  • It is important to appreciate that this explains the serious attention paid to astrology in ancient and medieval thought.
  • Direct correlations were made then by chroniclers of the period between celestial phenomena and political change – bearing in mind that most, if not all, chronicles were written after the fact.
  • A comet is a star which is not always visible, but which appears most frequently upon the death of a king, or on the destruction of a kingdom.
  • Another example, from September 13 1178, concerns the observation of the “horns” of the partially eclipsed Sun rotating to point towards the Earth.
  • This was followed in the same year by a cruel war and terrible bloodshed in those counties, and general disturbances happened throughout England, Wales and Ireland.

Today’s celestial spectacles

  • These days, celestial spectacles are seen as simply manifestations of the richness of a natural world that is explicable, at least in principle.
  • Nevertheless, despite the predictive success of, for example, the theory of gravity and classical dynamics, there are still problems that remain unpredictable.


Giles Gasper receives funding from the Arts and Humanities Research Council, UK, and The Leverhulme Trust Brian Tanner does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.